File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/ajg.2016.436
- Scopus: eid_2-s2.0-84988569126
- PMID: 27644733
- WOS: WOS:000394057300025
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy
Title | Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy |
---|---|
Authors | |
Issue Date | 2016 |
Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html |
Citation | American Journal of Gastroenterology, 2016, v. 111 n. 12, p. 1788-1795 How to Cite? |
Abstract | OBJECTIVES: Hepatitis B core-related antigen (HBcrAg) is a novel serum marker that correlates with intrahepatic hepatitis B virus (HBV) activity. Its association with HBV reactivation in hepatitis B surface antigen (HBsAg)-negative antibody to hepatitis B core antigen (anti-HBc)-positive patients undergoing high-risk immunosuppressive therapy is undefined.
METHODS: HBcrAg was measured in HBsAg-negative, anti-HBc-positive Asian patients with undetectable HBV DNA, who participated in two prospective studies investigating HBV reactivation during rituximab-containing chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). Patients were monitored every 4 weeks for up to 2 years, with entecavir started when HBV reactivation, defined as HBV DNA ≥10 IU ml−1, developed.
RESULTS: One hundred and twenty-four HBsAg-negative, anti-HBc-positive patients (rituximab, N =62; allogeneic HSCT, N =62) with a median follow-up of 64 weeks (range: 4–104 weeks) were studied. HBV reactivation occurred in 31 patients, with a 2-year cumulative reactivation rate of 40.4%. Serum HBcrAg was detected in 43 (34.7%) patients. Baseline HBcrAg positivity was significantly associated with HBV reactivation ( P =0.004, hazard ratio (HR): 2.94, 95% confidence interval (95% CI): 1.43–6.07). HBcrAg-positive patients had a significantly higher 2-year HBV reactivation rate than HBcrAg-negative patients (71.8 vs. 31%, P =0.002). In the rituximab cohort, the HRs for positive HBcrAg and negative antibody to HBsAg for HBV reactivation were 3.65 and 2.84, respectively ( P =0.011, 95% CI: 1.35–9.86 and P =0.032, 95% CI: 1.10–7.37, respectively).
CONCLUSIONS: Serum HBcrAg positivity is a significant risk factor of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing high-risk immunosuppressive therapy and can potentially have a role in identifying patients who will best benefit from prophylactic nucleoside analogue treatment. |
Persistent Identifier | http://hdl.handle.net/10722/232077 |
ISSN | 2023 Impact Factor: 8.0 2023 SCImago Journal Rankings: 2.391 |
ISI Accession Number ID | |
Errata |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Chan, SYT | - |
dc.contributor.author | Hwang, YYG | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Liu, SHK | - |
dc.contributor.author | Singh, GHH | - |
dc.contributor.author | Lam, YF | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Lie, AKW | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Kwong, YL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2016-09-20T05:27:33Z | - |
dc.date.available | 2016-09-20T05:27:33Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | American Journal of Gastroenterology, 2016, v. 111 n. 12, p. 1788-1795 | - |
dc.identifier.issn | 0002-9270 | - |
dc.identifier.uri | http://hdl.handle.net/10722/232077 | - |
dc.description.abstract | OBJECTIVES: Hepatitis B core-related antigen (HBcrAg) is a novel serum marker that correlates with intrahepatic hepatitis B virus (HBV) activity. Its association with HBV reactivation in hepatitis B surface antigen (HBsAg)-negative antibody to hepatitis B core antigen (anti-HBc)-positive patients undergoing high-risk immunosuppressive therapy is undefined. METHODS: HBcrAg was measured in HBsAg-negative, anti-HBc-positive Asian patients with undetectable HBV DNA, who participated in two prospective studies investigating HBV reactivation during rituximab-containing chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). Patients were monitored every 4 weeks for up to 2 years, with entecavir started when HBV reactivation, defined as HBV DNA ≥10 IU ml−1, developed. RESULTS: One hundred and twenty-four HBsAg-negative, anti-HBc-positive patients (rituximab, N =62; allogeneic HSCT, N =62) with a median follow-up of 64 weeks (range: 4–104 weeks) were studied. HBV reactivation occurred in 31 patients, with a 2-year cumulative reactivation rate of 40.4%. Serum HBcrAg was detected in 43 (34.7%) patients. Baseline HBcrAg positivity was significantly associated with HBV reactivation ( P =0.004, hazard ratio (HR): 2.94, 95% confidence interval (95% CI): 1.43–6.07). HBcrAg-positive patients had a significantly higher 2-year HBV reactivation rate than HBcrAg-negative patients (71.8 vs. 31%, P =0.002). In the rituximab cohort, the HRs for positive HBcrAg and negative antibody to HBsAg for HBV reactivation were 3.65 and 2.84, respectively ( P =0.011, 95% CI: 1.35–9.86 and P =0.032, 95% CI: 1.10–7.37, respectively). CONCLUSIONS: Serum HBcrAg positivity is a significant risk factor of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing high-risk immunosuppressive therapy and can potentially have a role in identifying patients who will best benefit from prophylactic nucleoside analogue treatment. | - |
dc.language | eng | - |
dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html | - |
dc.relation.ispartof | American Journal of Gastroenterology | - |
dc.title | Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy | - |
dc.type | Article | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Chan, SYT: drtchan@hku.hk | - |
dc.identifier.email | Hwang, YYG: yyhwang@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Liu, SHK: drkliu@hku.hk | - |
dc.identifier.email | Singh, GHH: gillhsh@hku.hk | - |
dc.identifier.email | Lam, YF: fyflam@hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Lie, AKW: akwlie@hkucc.hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Kwong, YL: ylkwong@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Singh, GHH=rp01914 | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Kwong, YL=rp00358 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1038/ajg.2016.436 | - |
dc.identifier.pmid | 27644733 | - |
dc.identifier.scopus | eid_2-s2.0-84988569126 | - |
dc.identifier.hkuros | 266801 | - |
dc.identifier.hkuros | 304362 | - |
dc.identifier.volume | 111 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 1788 | - |
dc.identifier.epage | 1795 | - |
dc.identifier.isi | WOS:000394057300025 | - |
dc.publisher.place | United States | - |
dc.relation.erratum | doi:10.1038/ajg.2016.510 | - |
dc.relation.erratum | eid:eid_2-s2.0-85003691671 | - |
dc.identifier.issnl | 0002-9270 | - |